---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-007347"
form_type: "8-K"
ticker: "ENVB"
cik: "0000890821"
company_name: "Enveric Biosciences, Inc."
filed_at: "2024-02-21T23:59:59+00:00"
generated_at: "2026-06-05T22:33:42.134027+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# ENVB unveils library of 57+ preclinical compounds targeting mental health disorders

## Summary
- Library spans 7 molecule classes including SNDRIs, NSRIs, MDMA derivatives, psilocin prodrugs, and melatonin agonists.
- Compounds are protected by Enveric's IP portfolio and represent potential out-licensing and non-dilutive revenue streams.
- Lead candidates EB-003 (non-hallucinogenic neuroplastogen) and EB-002 (psilocin prodrug) remain focus; library adds depth.
- Novel MDMA derivatives show varying 5-HT2A binding; some designed to reduce hallucinogenic potential while retaining neuroplasticity.

## SEC filing metadata
- accession: 0001493152-24-007347
- form_type: 8-K
- ticker: ENVB
- cik: 0000890821
- company_name: Enveric Biosciences, Inc.
- filed_at: 2024-02-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/890821/000149315224007347/0001493152-24-007347-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/890821/000149315224007347/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-007347
- JSON: https://secwatch.observer/filing/0001493152-24-007347.json
- Plain text: https://secwatch.observer/filing/0001493152-24-007347.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.